Intel shares rise as Elon Musk touts potential Tesla chipmaking deal
Arteris, Inc. (NASDAQ:AIP) VP and General Counsel Paul L. Alpern, sold 5,000 shares of common stock on November 3, 2025, for a total of $65,810. The sales occurred at prices ranging from $12.98 to $13.59. Since the transaction, AIP shares have climbed to $15.53, representing a 16.7% gain in just one week. According to InvestingPro data, the stock is currently trading near its 52-week high of $15.92 and appears overvalued based on Fair Value estimates. On the same day, Alpern also exercised options to acquire 5,000 shares of Arteris common stock at a price of $0.56, for a total value of $2,800.
The sale was executed under a pre-arranged 10b5-1 trading plan adopted on June 5, 2025. Following the sale, Alpern directly owns 65,960 shares of Arteris, Inc.
The option exercise relates to options that vest according to a specific schedule, with 25% vesting on August 26, 2020, and the remainder vesting monthly over three years, beginning September 26, 2020. The options expire on October 23, 2029. Following the transaction, Alpern directly owns 80,000 derivative securities.Analysts maintain a "Strong Buy" consensus on Arteris with price targets ranging from $15 to $20. For deeper insights into AIP’s financial health (rated "Fair" by InvestingPro), including exclusive ProTips and a comprehensive Pro Research Report, upgrade to access analysis on this and 1,400+ other US equities.
In other recent news, Arteris Inc. reported its third-quarter earnings for 2025, showing a revenue of $17.4 million, which marks an 18% increase compared to the previous year and surpasses the forecasted $17 million. The company’s earnings per share (EPS) met expectations at -$0.09. Despite these positive financial results, Arteris’ stock experienced a decline in aftermarket trading. Additionally, Rosenblatt Securities raised its price target for Arteris to $20 from $14, maintaining a Buy rating. This adjustment follows what Rosenblatt described as a "beat-n-raise report," highlighting expanded licenses with Altera and AMD and new FlexGen license additions. These recent developments indicate a strong performance for the company, according to Rosenblatt.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.